Botulinum toxin injections for pediatric patients with hereditary spastic paraparesis

Journal of Child Neurology

Volumn 25, Issue 8, 2010, Pages 969-975

  Geva Dayan, Keren ^a   Domenievitz, Dafna ^a   Zahalka, Rafat ^a   Fattal Valevski, Aviva ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

botulinum toxin A; hereditary spastic paraparesis; lower extremity

Indexed keywords

BOTULINUM TOXIN A;

ADJUVANT THERAPY; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROCNEMIUS MUSCLE; GROSS MOTOR FUNCTION MEASURE; HAMSTRING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LEARNING DISORDER; MALE; MEDICAL RECORD REVIEW; MILD COGNITIVE IMPAIRMENT; MOTOR ACTIVITY; MOTOR PERFORMANCE; MUSCLE TONE; PEDIATRICS; PRIORITY JOURNAL; SEX RATIO;

ACTIVITIES OF DAILY LIVING; BOTULINUM TOXINS, TYPE A; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RETROSPECTIVE STUDIES; SPASTIC PARAPLEGIA, HEREDITARY; TREATMENT OUTCOME;

EID: 77954698260     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073809356037     Document Type: Article

References (26)

1. Harding AE Hereditary "pure" spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry. 1981 ; 44: 871-883.
2. McDermott CJ, White K., Bushby K., Shaw PJ Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000 ; 69: 150-160.
3. Depienne C., Stevanin G., Brice A., Durr A. Hereditary spastic paraplegias: an update. Curr Opin Neurol. 2007 ; 20: 674-680.
4. Hentati A., Deng HX, Zhai H., et al. Novel mutations in spastin gene and absence of correlation with age at onset of symptoms. Neurology. 2000 ; 55: 1388-1390.
5. Appleton RE, Farrell K., Dunn HG Pure and complicated forms of hereditary spastic paraplegia presenting in childhood. Dev Med Child Neurol. 1991 ; 33: 304-312.
6. Harding AE Classification of the hereditary ataxias and paraplegias. Lancet. 1983 ; 1: 1151-1155.
7. Bruyn RP The neuropathology of hereditary spastic paraparesis. Clin Neurol Neurosurg. 1992 ; 94 (suppl): s16 - s18.
8. Stevanin G., Ruberg M., Brice A. Recent advances in the genetics of spastic paraplegias. Curr Neurol Neurosci Rep. 2008 ; 8: 198-210.
9. Depienne C., Tallaksen C., Lephav JY, et al. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet. 2006 ; 43: 259-265.
10. Bürger J., Fonknechten N., Hoeltzenbein M., et al. Hereditary spastic paraplegia caused by mutations in the SPG4 gene. Eur J Hum Genet. 2000 ; 8: 771-776.
11. McDermott CJ, Burness CE, Kirby J., et al. Clinical features of hereditary spastic paraplegia due to spastin mutation. Neurology. 2006 ; 67: 45-51.
12. Meythaler JM, Steers WD, Tuel SM, et al. Intrathecal baclofen use in hereditary spastic paraparesis. Arch Phys Med Rehabil. 1992 ; 73: 794-797.
13. Lambrecq V., Muller F., Joseph PA, et al. Intrathecal baclofen in hereditary spastic paraparesis: benefits and limitations. Ann Read-apt Med Phys. 2007 ; 50: 577-581.
14. Ward AB Spasticity treatment with botulinum toxins. J Neural Transm. 2008 ; 115: 607-616.
15. Sarioglu B., Serdaroglu G., Tutuncuoglu S., Ozer EA The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol. 2003 ; 29: 299-301.
16. Dunne JW, Heye N., Dunne SL Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry. 1995 ; 58: 232-235.
17. Rousseaux M., Launay MJ, Kozlowski O., Daveluy W. Botulinum toxin injection in patients with hereditary spastic paraparesis. Eur J Neurol. 2007 ; 14: 206-212.
18. Hecht MJ, Stolze H., Auf dem Brinke M., et al. Botulinum neuro-toxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia: report of 19 cases. Mov Disord. 2008 ; 23: 228-233.
19. Russell DJ, Rosenbaum PL, Cadman DT, et al. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989 ; 31: 341-352.
20. Devon RS, Helm JR, Rouleau GA, et al. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet. 2003 ; 64: 210-215.
21. Lesca G., Eymard-Pierre E., Santorelli FM, et al. Infantile ascending hereditary spastic paralysis (IAHSP) clinical features in 11 families. Neurology. 2003 ; 60: 674-682.
22. Eymard-Pierre E., Lesca G., Dollet S., et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet. 2002 ; 71: 518-527.
23. Bjornson K., Hays R., Graubert C., et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007 ; 120: 49-58.
24. Goldstein EM Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol. 2006 ; 21: 189-192.
25. Fattal-Valevski A., Domenievitz D., Giladi N., et al. Long term effect of repeated injections of botulinum toxin in children with cerebral palsy: a prospective study. J Child Orthop. 2008 ; 2: 29-35.
26. Herrman J., Geth K., Mall V., et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 2004 ; 55: 732-735.